Show simple item record

dc.contributor.authorSuliman, AS
dc.contributor.authorKhoder, M
dc.contributor.authorTolaymat, I
dc.contributor.authorWebster, M
dc.contributor.authorAlany, RG
dc.contributor.authorWang, W
dc.contributor.authorElhissi, A
dc.contributor.authorNajlah, M
dc.date.accessioned2021-02-19T09:37:01Z
dc.date.available2021-02-19T09:37:01Z
dc.date.issued2021-01-10
dc.identifier.citationSaid Suliman A, Khoder M, Tolaymat I, Webster M, Alany RG, Wang W, Elhissi A, Najlah M. (2021) Cyclodextrin Diethyldithiocarbamate Copper II Inclusion Complexes: A Promising Chemotherapeutic Delivery System against Chemoresistant Triple Negative Breast Cancer Cell Lines. Pharmaceutics. 2021; 13(1):84. https://doi.org/10.3390/pharmaceutics13010084en
dc.identifier.issn1999-4923en
dc.identifier.pmid33435151 (pubmed)
dc.identifier.doi10.3390/pharmaceutics13010084en
dc.identifier.urihttp://hdl.handle.net/2436/623944
dc.description© 2021 The Authors. Published by MDPI. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.3390/pharmaceutics13010084en
dc.description.abstractDiethyldithiocarbamate Copper II (DDC-Cu) has shown potent anticancer activity against a wide range of cancer cells, but further investigations are hindered by its practical insolubility in water. In this study, inclusion complexes of DDC-Cu with hydroxypropyl beta-cyclodextrin (HP) or sulfobutyl ether beta-cyclodextrin (SBE) were prepared and investigated as an approach to enhance the apparent solubility of DDC-Cu. Formulations were prepared by simple mixing of DDC-Cu with both cyclodextrin (CDs) at room temperature. Phase solubility assessments of the resulting solutions were performed. DDC-Cu CD solutions were freeze-dried for further characterisations by DSC, thermogravimetric analysis (TGA) and FT-IR. Stability and cytotoxicity studies were also performed to investigate the maintenance of DDC-Cu anticancer activity. The phase solubility profile deviated positively from the linearity (Ap type) showing significant solubility enhancement of the DDC-Cu in both CD solutions (approximately 4 mg/mL at 20% w/w CD solutions). The DSC and TGA analysis confirmed the solid solution status of DDC-Cu in CD. The resulting solutions of DDC-Cu were stable for 28 days and conveyed the anticancer activity of DDC-Cu on chemoresistant triple negative breast cancer cell lines, with IC50 values less than 200 nM. Overall, cyclodextrin DDC-Cu complexes offer a great potential for anticancer applications, as evidenced by their very positive effects against chemoresistant triple negative breast cancer cells.en
dc.description.sponsorshipThis research is funded by NPRP grant (NPRP9-337-3-069) from the Qatar National Research Fund (a member of Qatar Foundation).en
dc.formatapplication/pdfen
dc.languageeng
dc.language.isoenen
dc.publisherMDPIen
dc.relation.urlhttps://www.mdpi.com/1999-4923/13/1/84en
dc.rightsLicence for published version: Creative Commons Attribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectbeta-cyclodextrinen
dc.subjectChemoresistanceen
dc.subjectdiethyldithiocarbamate copper IIen
dc.subjectSolubilityen
dc.subjecttriple negative breast canceren
dc.titleCyclodextrin diethyldithiocarbamate copper ii inclusion complexes: A promising chemotherapeutic delivery system against chemoresistant triple negative breast cancer cell linesen
dc.typeJournal articleen
dc.identifier.eissn1999-4923
dc.identifier.journalPharmaceuticsen
dc.date.updated2021-02-16T00:56:53Z
dc.contributor.institutionPharmaceutical Research Group, School of Allied Health, Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University, Bishops Hall Lane, Chelmsford CM1 1SQ, UK.
pubs.place-of-publicationSwitzerland
dc.date.accepted2021-01-05
rioxxterms.funderQatar National Research Funden
rioxxterms.identifier.projectNPRP9-337-3-069en
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2021-02-19en
dc.source.volume13
dc.source.issue1
dc.source.beginpage1
dc.source.endpage12
dc.description.versionPublished version
refterms.dateFCD2021-02-19T09:36:51Z
refterms.versionFCDVoR
refterms.dateFOA2021-02-19T09:37:02Z


Files in this item

Thumbnail
Name:
Cyclodextrin Diethyldithiocarbamate ...
Size:
3.257Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Licence for published version: Creative Commons Attribution 4.0 International
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International